ER-100 Clinical Trial for Glaucoma: What We Know So Far and What to Expect

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/er-100-clinical-trial-for-glaucoma-what-we-know-so-far-and-what-to-expect

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

ER-100: A New Gene Therapy Trial for Glaucoma and Optic NeuropathiesGlaucoma is a leading cause of permanent vision loss worldwide. It happens when the delicate nerves that carry images from the eye to the brain (the retinal ganglion cells, or RGCs) are damaged or die. In most glaucoma patients, this nerve damage is linked to high intraocular pressure (eye pressure), so current treatments (eye drops, lasers, or surgery) focus on lowering that pressure () (). However, even with good pressure control, many patients continue to lose vision over time. In fact, some people develop “normal-tension” glaucoma, where their eye pressure is never high, yet the optic nerve still deteriorates () (). This shows that glaucoma therapies based only on pressure relief can slow the disease but cannot reverse it. Another related condition, non-arteritic anterior ischemic optic neuropathy (NAION), causes sudden vision loss due to poor blood flow to the optic nerve (often called “stroke of the eye”). Unfortunately, there are no approved treatments for NAION, so patients have to wait and hope for some natural recovery, which often never comes (). Because of these gaps – few ways to actually protect or restore the optic nerve – researchers are excited about a completely new approach called ER-100. This is an experimental gene therapy being tested in a Phase 1 clinical trial (starting in 2026) for people with open-angle glaucoma or recent NAION. ER-100 does not target eye pressure at all. Instead, it aims to rejuvenate the aged or damaged cells in the retina and optic nerve by turning back their “cellular clock” () (). In simple terms, ER-100 delivers genetic instructions to the eye’s nerves that may help them behave like younger, healthier cells. How ER-100 Works: “Partial Reprogramming” of Eye CellsER-100 is a first-of-its-kind therapy based on partial epigenetic reprogramming. It makes use of a discovery by Nobel laureate Dr. Shinya Yamanaka (who found that certain genes can reset a cell’s age). Specifically, ER-100 carries three of the four Yamanaka genes – OCT4, SOX2, and KLF4 (often abbreviated OSK) – into the eye (). These genes are delivered by harmless viruses (modified adeno-associated viruses, or AAVs) injected directly into the gel of the eye (the vitreous) (). Once in the retinal nerve cells, the viral carrier gives those cells the instructions to make the OSK proteins. The idea is that the OSK proteins will reset some of the cells’ molecular markers – their epigenetic marks – restoring a more youthful gene activity pattern without actually changing the cells’ DNA () (). Importantly, ER-100 uses a safety feature: the OSK genes are under control of a “switch” that responds to doxycycline, a common antibiotic () (). Patients in the trial will take low-dose doxycycline for about 8 weeks after the injection. This enables the OSK genes to turn on only during treatment. Once the doxycycline is stopped, the cells reduce OSK activity. This makes it transient gene therapy (temporary gene expression) aimed just at re-setting cell age rather than permanently changing the cells. Because ER-100 only delivers three factors (leaving out the fourth Yamanaka factor, c-Myc, which is linked to tumor risk), the company hopes